Plain-English translation of NCT07027254 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding a new imaging scan called Gallium-68 Pentixafor PET-CT to standard adrenal vein sampling (a catheter-based test) helps doctors make better decisions about adrenal gland surgery in patients with primary aldosteronism, a condition where the adrenal gland produces too much of a hormone called aldosterone. Right now, doctors use a catheter-based test to figure out which patients need surgery, but this test can be difficult and doesn't always work. The new imaging scan may give doctors clearer information to help them choose the right patients for surgery.
Many patients with primary aldosteronism have high blood pressure that is hard to control, and surgery can help them. However, doctors need an accurate way to identify which patients will truly benefit from surgery. The current gold-standard test is invasive and difficult, so this trial is testing whether a safer, easier imaging scan can give doctors the information they need to make better treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group will receive the standard catheter-based test alone, and the other group will receive that same test plus the new imaging scans. Both groups will then move forward with surgery decisions based on the results. The trial is designed to see whether patients in the group receiving the additional imaging scans have better surgical outcomes and better control of their blood pressure after surgery. Your doctors will track your health and blood pressure for some time after your surgery to compare the results between the two groups.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
South Korea